Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Not applicableLooking for participantsNCT04090034
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System 50
Not applicableLooking for participantsNCT07302100
What this trial is testing

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Not applicableStudy completedNCT02948946
What this trial is testing

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm
H. Lee Moffitt Cancer Center and Research Institute 105
Not applicableLooking for participantsNCT06155318
What this trial is testing

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
IRCCS San Raffaele 300
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Very early researchLooking for participantsNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Testing effectiveness (Phase 2)Study completedNCT03043664
What this trial is testing

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Duke University 22
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Early research (Phase 1)Ended earlyNCT05364944
What this trial is testing

Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
AcromegalyGEP-NET
Debiopharm International SA 19
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Not applicableActive Not RecruitingNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Load More Results